Sunday, September 19, 2021

Tag: cancer

Broader Role for PARP Inhibitors in Breast Cancer?

Homologous recombination deficiency (HRD) predicted most responses to the PARP inhibitor olaparib (Lynparza) in patients with triple-negative breast cancer (TNBC), including patients without germline (g)BRCA or PALB2 mutations, a small clinical trial showed.

Overall, 18 of 32 TNBCs responded to primary treatment with olaparib, and HRD was present in 16 of 18 responding tumors. A majority of responses occurred in tumors without germline mutations, in contrast to conventional wisdom about PARP inhibitors’ activity in breast cancer.

“Olaparib monotherapy yielded a high response rate when administered to treatment-naïve, large TNBC, with germline or somatic HR deficiency,” reported Hans Petter Eikesdal, MD, of the University of Bergen in Norway, and colleagues in the Annals of Oncology. “While the benefit of PARP inhibitor monotherapy in TNBC needs confirmation, it presents a potential sequential approach for TNBC downstaging prior to chemotherapy.”

PARP inhibitors’ have established antitumor activity in breast cancers

Read More
Pregnancy Less Common in Young Breast Cancer Survivors

Younger women with a history of breast cancer are less likely to get pregnant compared to the general public, and their babies face a higher risk of certain adverse outcomes when they do, a large meta-analysis found.

Compared with the population at large, breast cancer survivors of childbearing age were 60% less likely to go on to have a pregnancy (relative risk 0.40, 95% CI 0.32-0.49, P<0.001), reported Eva Blondeaux, MD, of IRCCS Policlinico San Martino Hospital in Genoa, Italy.

Among all women with cancer, only those with cervical cancer were less likely to undergo pregnancy following treatment (RR 0.33, 95% CI 0.32-0.49, P<0.001), according to findings presented at the virtual San Antonio Breast Cancer Symposium (SABCS).

“The reduced chance of future conception among breast cancer survivors raises awareness on the importance of offering complete oncofertility counseling at diagnosis to all young women,” Blondeaux said, but she added

Read More
Online Tool Refines Individual Risks in Breast Cancer

SAN ANTONIO — An online tool, which incorporates clinicopathological data and the results of the 21-gene recurrent score, was able to estimate risk of distant recurrence (DR) and adjuvant chemotherapy benefit in certain patients with breast cancer, a researcher reported.

The RSClin tool integrates the recurrence score (RS) with tumor grade, tumor size, and age using a patient-specific meta-analysis that included 10,004 women with hormone receptor-positive, HER2-negative, and node-negative breast cancer who received endocrine therapy alone in the B-14 trial, or with chemotherapy in the TAILORx trial, explained Joseph Sparano, MD, of Montefiore Medical Center and the Albert Einstein College of Medicine in New York City, at the San Antonio Breast Cancer Symposium virtual meeting. The study was simultaneously published in the Journal of Clinical Oncology.

“In external validation, the RSClin risk estimate was prognostic for disease recurrence risk in the Clalit registry (P<0.001) and the estimated

Read More
Op-Ed: How Trump’s New Drug Pricing Scheme Hurts Cancer Patients

For many Americans, over the last decade, cutting-edge therapies and technology have changed the words “you have cancer” from a death sentence to a chronic disease, where quality of life and survival are preserved for many of our patients who in the past might not have been so lucky. Just this year alone there has been an extraordinary wave of more than a dozen new treatment options for patients that bring with them hope, comfort, longevity, the ability to continue contributing to society, and enhanced time with their loved ones. Why then does President Trump want to limit access to these lifesaving drugs with his misguided “Most Favored Nation” (MFN) model?

The stated purpose of the MFN model is to reduce the cost of drugs for the Medicare program. It will do this by benchmarking what the United States government pays for the top 50 Medicare Part B drugs to

Read More
Mindfulness meditation reduces symptoms of depression in younger breast cancer survivors

breast cancer
Credit: CC0 Public Domain

New UCLA-led research shows that behavioral interventions—mindfulness meditation and survivorship education classes—are effective in reducing depressive symptoms in younger breast cancer survivors, who often experience the highest levels of depression, stress and fatigue that can persist for as long as a decade after their diagnosis.

The results, presented at the San Antonio Breast Cancer Symposium (ABSTRACT GS2-10), highlights how six-week interventions can reduce depression in younger women treated for breast cancer, and in the case of mindfulness meditation, improve related symptoms such as fatigue and sleep disturbance.

About 20% of breast cancer cases occur in women younger than 50. Persistent depressive symptoms, lasting two weeks or more, are especially problematic in this target population.

“For women in their 30s and 40s, the experience with breast cancer and its treatments is substantially different from that of older women,” said lead author Dr. Patricia Ganz, associate director for

Read More